BRISTOL MYERS SQUIBB CO
CELG-RIDrugs in Pipeline
247
Phase 3 Programs
125
Upcoming Catalysts
19
Next Catalyst
This month
Market Overview
Stock performance and key metrics
19 upcoming, 2 past
Afimetoran Phase 2 Est. Readout
Estimated primary completion for Afimetoran trial (NCT04895696) in Systemic Lupus Erythematosus. Topline data typically follows completion by weeks to months.
Source18 more catalysts beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Opdivo
Renal Cell Carcinoma
Asunaprevir
Hepatitis C
BMS-936558
Unresectable or Metastatic Melanoma
DCV
Hepatitis C
Entecavir
Hepatitis B, Chronic
Relatlimab
Advanced Gastric Cancer
Cisplatin
Non Small Cell Lung Cancer
Paclitaxel
Breast Cancer
Videx EC
HIV Infections
Daclatasvir
Hepatitis C Infection
BMS-986205
Advanced Cancer
Etoposide
Small Cell Lung Carcinoma
Apremilast
Psoriatic Arthritis
Ustekinumab
Plaque Psoriasis
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)
Rheumatoid Arthritis
Tenofovir
Chronic Hepatitis B
Oxaliplatin
Colorectal Cancer
Muraglitazar
Metabolics Diabetes Nos
Oral Azacitidine
Myelodysplastic Syndromes
Atazanavir (immediate switch)
HIV Infections
Imatinib
Chronic Myeloid Leukemia
Cabozantinib
Renal Cell Carcinoma
Telaprevir
Hepatitis C
Carboplatin
Pediatric Solid Tumors
Cyclosporine (CsA)
Kidney Transplantation
Xanomeline and Trospium Chloride Capsules
Schizophrenia
MDX-010 (anti-CTLA4) monoclonal antibody
Melanoma
Elotuzumab
Multiple Myeloma
Paclitaxel and carboplatin
Carcinoma, Non-Small-Cell Lung
Pegylated interferon lambda (pegIFNλ)
Hepatitis C Virus (HCV)
Prednisone
Prostate Cancer
Atazanavir + Ritonavir
Human Immunodeficiency Virus (HIV) Infections
Sorafenib
Hepatocellular Carcinoma
Atazanavir
HIV Infections
Irbesartan
Atrial Fibrillation
stavudine, efavirenz, lamivudine
HIV Infections
Lamivudine/Zidovudine
HIV Infections
Ribavirin
Hepatitis C
Adalimumab
Rheumatoid Arthritis
Mezigdomide
Relapsed or Refractory Multiple Myeloma
Methotrexate
Rheumatoid Arthritis
DCV/ASV/BMS-791325
Hepatitis C Virus
Subcutaneous (SC) Abatacept
Rheumatoid Arthritis (RA)
SAR302503
Hematopoietic Neoplasm
Peg-interferon Alfa-2a
Hepatitis C Virus
Dacarbazine
Melanoma
Everolimus
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Peginterferon Alfa-2a
Hepatitis C
pexacerfont
Generalized Anxiety Disorder
Gemcitabine
Stage IV or Recurrent Non-Small Cell Lung Cancer
Iza-bren
Urothelial Cancer
vinflunine
Transitional Cell Carcinoma
rHuPH20
Melanoma
Didanosine
HIV Infections
Ozanimod
Multiple Sclerosis, Relapsing-Remitting
Enoxaparin
Deep Vein Thrombosis
Stavudine
HIV Infections
Irbesartan monotherapy
Hypertension
Epoetin Alfa
Myelodysplastic Syndromes
Bempegaldesleukin
Bladder Cancer
Pemetrexed
Mesothelioma, Malignant
Lithium
Bipolar Disorder Type I With Mania
Fluorouracil
Various Advanced Cancer
Xanomeline/Trospium Chloride Capsule
Alzheimer Disease
Methotrexate (MTX)
Rheumatoid Arthritis (RA)
Irbesartan/HCTZ
Hypertension
Iberdomide
Multiple Myeloma
Sunitinib
Advanced Renal Cell Carcinoma
Peginterferon Lambda-1a
Hepatitis C Virus (HCV)
atazanavir/ritonavir +2 NRTIs (immediate Switch Group)
HIV Infections
Atazanavir Sulphate
HIV
Atazanavir powder
HIV Infections
Deucravacitinib
Psoriatic Arthritis
Pomalidomide
Multiple Myeloma
Pegylated-Interferon-lambda
Hepatitis C Virus
BMS-986353
Systemic Sclerosis
Glucovance (metformin HCl/glyburide)
Diabetes Mellitus, Non-Insulin-Dependent
ATV
HIV Infections
Atazanvir/ritonavir + efavirenz
HIV Infections
Atazanavir+ritonavir
HIV Infections
Belatacept
Renal Transplantation
Tacrolimus
Renal Allograft Recipients
Lenalidomide
Multiple Myeloma
Bortezomib
Multiple Myeloma
Nelfinavir mesylate
HIV Infections
Mavacamten
Cardiomyopathy, Hypertrophic
PEG-Interferon alfa 2a
Hepatitis C, Genotype 1
Tanespimycin
Advanced Malignancies
Docetaxel
Non-Small Cell Lung Cancer
Apixaban
Lymphoma
Brivanib
Hepato Cellular Carcinoma (HCC)
BMS-986278
Idiopathic Pulmonary Fibrosis
Sofosbuvir
Hepatitis C
Double-blind Abatacept
Rheumatoid Arthritis
Sorivudine
HIV Infections
Atazanavir/Ritonavir
HIV
KarX-EC
Alzheimer's Disease
BMS-986165
Psoriasis
KarXT
Alzheimer Disease
dasatinib
Myeloid Leukemia, Chronic, Accelerated Phase
Pioglitazone
Type 2 Diabetes Mellitus
Xanomeline/Trospium Chloride
Mania
warfarin
Venous Thrombosis
Efavirenz
HIV Infections
Adefovir
Hepatitis B, Chronic
Cyclosporin A
Renal Transplantation
Xanomeline Enteric Capsule
Alzheimer Disease
BMS-790052 (NS5A Replication Complex Inhibitor)
Hepatitis C
DCV 3DAA
Hepatitis C Virus Infection
Luspatercept
Myelodysplastic Syndromes
Acetylsalicylic acid
Atrial Fibrillation
Atazanavir + ritonavir + tenofovir + nucleoside
HIV Infections
BMS-986504
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
abatacept (ABA)
Ulcerative Colitis
pegIFNα-2b
Hepatitis C Virus Infection
Temozolomide
Brain Cancer
nab-Paclitaxel
Non-Small Cell Lung Cancer
Abatacept
Rheumatoid Arthritis
Abatacept subcutaneous
Polymyositis
Cetuximab
Squamous Cell Carcinoma of the Head and Neck
Pumitamig
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Rheumatoid Arthritis
Asunaprevir (ASV)
Hepatitis C Virus
Capecitabine
Gastric Cancer
Antidepressant + Aripiprazole
Major Depressive Disorder
Leucovorin
Metastatic Colorectal Cancer
Simeprevir
Hepatitis C Virus
BMS-754807
Breast Cancer
Aurexis®
Staphylococcus Aureus Bacteremia
Vitamin K Antagonist (VKA)
Thrombosis
Letrozole
Metastatic Breast Cancer
CXL-1020
Heart Failure
Oral Taxane
Non-small Cell Lung Cancer
BMS-986253
Cancer
BMS-986322
Psoriasis
BMS-986490
Advanced Solid Tumors
MYK-491
Heart Failure With Reduced Ejection Fraction
PSI-7977
Chronic Hepatitis C
200 mg INX-08189 Fasted
Hepatitis C
unfractionated heparin (UFH)
Antithrombotic
MORAb-202
Neoplasms, Ovarian
BMS-986523
Advanced Solid Malignancies
BMS-986259
Acute Decompensated Heart Failure
BMS-986036
Non-Alcoholic Steatohepatitis
BMS-823778
Dyslipidemia
Lirilumab
Non-Hodgkin's Lymphoma
Duloxetine
Depression
MDX-1100
Rheumatoid Arthritis
BMS-986213
Advanced Solid Tumors
Trametinib
Cancer
BMS-986158
Myelofibrosis
BMS-986020
Idiopathic Pulmonary Fibrosis
BMS-830216
Obesity
Strata 1 CXL-1020
Heart Failure
carboplatin + irinotecan
Neoplasms
BMS-986340
Cervical Cancer
Anastrozole
Breast Cancer
BMS-986446
Alzheimer Disease, Early Onset
SAR302503 (TG101348)
Myelofibrosis
HNO Donor
Heart Failure
BMS-986435
Heart Failure
ixabepilone
Esophageal Cancer
Cyclophosphamide
Breast Cancer
BMS-790052
Hepatitis C Infection
BMS-986142
Rheumatoid Arthritis
CC-92480
Multiple Myeloma
Cabiralizumab
Advanced Pancreatic Cancer
CXL-1427
Heart Failure
Peginterferon α-2a
Hepatitis C
BMS-986156
Solid Tumors
MDX-010 / MDX-010 + Docetaxel
Prostate Cancer
Lamivudine
Hepatitis B Virus
BMS-986458
Relapsed/Refractory Non-Hodgkin Lymphoma
Thymoglobulin
Kidney Transplantation
BMS-690514
Non-Small-Cell Lung Carcinoma
Cyclosporine A
Renal Transplant
Ritonavir
HIV Infections
Dexamethasone
Multiple Myeloma
Abatacept (BMS-188667)
Rheumatoid Arthritis
BMS-986288
Advanced Cancer
BMS-650032
Hepatitis C Virus
CC-486
Leukemia, Myeloid, Acute
BMS-986141
Thrombosis
Aurexis® (tefibazumab)
Staphylococcus Aureus
Cabazitaxel
Prostate Cancer
Pegylated Interferon Lambda
Hepatitis C
Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
HIV Infections
BMS-986369
Relapsed or Refractory T-cell Lymphomas
5-fluorouracil (5-FU)
Colorectal Cancer
Peginterferon alpha-2a
Hepatitis C Infection
Exemestane + Dasatinib
Breast Cancer
Dasatinib 100 mg
Breast Cancer
MDX-010
Breast Cancer
BMS-986004 75 mg IV
Immune Thrombocytopenic Purpura
Vemurafenib
Melanoma
KOS-1584
Non-Small Cell Lung Cancer
INX-08189 50 mg
Healthy
Pegylated-interferon alfa-2a
Chronic Hepatitis C
BMS-708163
Alzheimer's Disease
BMS-954561
Diabetic Peripheral Neuropathic Pain
CCR2 Antagonist
Type 2 Diabetes
BMS-986012 (anti-fucosyl-GM1)
Small Cell Lung Cancer
BMS-986482
Advanced Solid Tumors
BMS-791325
Hepatitis C Virus
Daratumumab
Advanced Cancer
BMS-562086
Irritable Bowel Syndrome
Elotuzumab (BMS-901608)
Multiple Myeloma
BMS-986012
Extensive-stage Small Cell Lung Cancer
BMS-833923
Leukemia
BMS-986165 Dose A
Active Psoriatic Arthritis
BMS-986315
Advanced Solid Tumor
BMS-986470
Anemia, Sickle Cell
BMS-790052 (NS5A Inhibitor)
Hepatitis C
BMS-986525
Relapsed/Refractory Small Cell Lung Cancer
BMS-813160
Advanced Cancer
Sirolimus
Disorder Related to Renal Transplantation
BMS-914392
Atrial Fibrillation
Erlotinib
Non Small Cell Lung Cancer
branebrutinib
Autoimmune Disorder
Fulvestrant
Advanced Breast Cancer
Megestrol acetate
Anorexia
BMS-582949
Vascular Diseases
Cobimetinib
Microsatellite Unstable Colorectal Cancer
Afimetoran
Systemic Lupus Erythematosus
BMS-820836
Depression
pegIFN
Hepatitis B Virus
Thalidomide
Relapsed and/or Refractory Multiple Myeloma
BMS-986449
Advanced Solid Tumors
Pegylated interferon alfa-2a
Hepatitis C Virus
Cyclosporine
Graft Rejection
Irinotecan
Colorectal Cancer (CRC)
Anti-CD137 (4-1BB) (BMS-663513)
Melanoma
BMS-777607
Advanced Solid Tumors
Fedratinib
Primary Myelofibrosis
BMS-986231
Cardiac Failure
BMS-908662
Colorectal Cancer
BMS-770767
Diabetes Type 2
BMS-986507
Lung Cancer
BMS-986263
Hepatic Cirrhosis
INX-08189 50 mg QD X 5 days
Healthy
bendamustine
Hodgkin Disease
BMS-936557 (Anti-IP-10 Antibody)
Crohn's Disease
brivanib (active)
Hepatocellular Carcinoma (HCC)
MDX-010 (CTLA-4)
Melanoma
BMS-986249
Advanced Cancer
BMS-986207
Broad Solid Tumor
BMS-986517
Solid Tumours
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Opdivo | Approved | Renal Cell Carcinoma | - | - |
Asunaprevir | Phase 3 | Hepatitis C | - | - |
BMS-936558 | Phase 3 | Unresectable or Metastatic Melanoma | - | - |
DCV | Phase 3 | Hepatitis C | - | - |
Entecavir | Phase 3 | Hepatitis B, Chronic | - | - |
Relatlimab | Phase 3 | Advanced Gastric Cancer | - | - |
Cisplatin | Phase 3 | Non Small Cell Lung Cancer | - | - |
Paclitaxel | Phase 3 | Breast Cancer | - | - |
Videx EC | Phase 3 | HIV Infections | - | - |
Daclatasvir | Phase 3 | Hepatitis C Infection | - | - |
BMS-986205 | Phase 3 | Advanced Cancer | - | - |
Etoposide | Phase 3 | Small Cell Lung Carcinoma | - | - |
Apremilast | Phase 3 | Psoriatic Arthritis | - | - |
Ustekinumab | Phase 3 | Plaque Psoriasis | - | - |
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Phase 3 | Rheumatoid Arthritis | - | - |
Tenofovir | Phase 3 | Chronic Hepatitis B | - | - |
Oxaliplatin | Phase 3 | Colorectal Cancer | - | - |
Muraglitazar | Phase 3 | Metabolics Diabetes Nos | - | - |
Oral Azacitidine | Phase 3 | Myelodysplastic Syndromes | - | - |
Atazanavir (immediate switch) | Phase 3 | HIV Infections | - | - |
Imatinib | Phase 3 | Chronic Myeloid Leukemia | - | - |
Cabozantinib | Phase 3 | Renal Cell Carcinoma | - | - |
Telaprevir | Phase 3 | Hepatitis C | - | - |
Carboplatin | Phase 3 | Pediatric Solid Tumors | - | - |
Cyclosporine (CsA) | Phase 3 | Kidney Transplantation | - | - |
Xanomeline and Trospium Chloride Capsules | Phase 3 | Schizophrenia | - | - |
MDX-010 (anti-CTLA4) monoclonal antibody | Phase 3 | Melanoma | - | - |
Elotuzumab | Phase 3 | Multiple Myeloma | - | - |
Paclitaxel and carboplatin | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Pegylated interferon lambda (pegIFNλ) | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Prednisone | Phase 3 | Prostate Cancer | - | - |
Atazanavir + Ritonavir | Phase 3 | Human Immunodeficiency Virus (HIV) Infections | - | - |
Sorafenib | Phase 3 | Hepatocellular Carcinoma | - | - |
Atazanavir | Phase 3 | HIV Infections | - | - |
Irbesartan | Phase 3 | Atrial Fibrillation | - | - |
stavudine, efavirenz, lamivudine | Phase 3 | HIV Infections | - | - |
Lamivudine/Zidovudine | Phase 3 | HIV Infections | - | - |
Ribavirin | Phase 3 | Hepatitis C | - | - |
Adalimumab | Phase 3 | Rheumatoid Arthritis | - | - |
Mezigdomide | Phase 3 | Relapsed or Refractory Multiple Myeloma | - | - |
Methotrexate | Phase 3 | Rheumatoid Arthritis | - | - |
DCV/ASV/BMS-791325 | Phase 3 | Hepatitis C Virus | - | - |
Subcutaneous (SC) Abatacept | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
SAR302503 | Phase 3 | Hematopoietic Neoplasm | - | - |
Peg-interferon Alfa-2a | Phase 3 | Hepatitis C Virus | - | - |
Dacarbazine | Phase 3 | Melanoma | - | - |
Everolimus | Phase 3 | Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma | - | - |
Peginterferon Alfa-2a | Phase 3 | Hepatitis C | - | - |
pexacerfont | Phase 3 | Generalized Anxiety Disorder | - | - |
Gemcitabine | Phase 3 | Stage IV or Recurrent Non-Small Cell Lung Cancer | - | - |
Iza-bren | Phase 3 | Urothelial Cancer | - | - |
vinflunine | Phase 3 | Transitional Cell Carcinoma | - | - |
rHuPH20 | Phase 3 | Melanoma | - | - |
Didanosine | Phase 3 | HIV Infections | - | - |
Ozanimod | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
Enoxaparin | Phase 3 | Deep Vein Thrombosis | - | - |
Stavudine | Phase 3 | HIV Infections | - | - |
Irbesartan monotherapy | Phase 3 | Hypertension | - | - |
Epoetin Alfa | Phase 3 | Myelodysplastic Syndromes | - | - |
Bempegaldesleukin | Phase 3 | Bladder Cancer | - | - |
Pemetrexed | Phase 3 | Mesothelioma, Malignant | - | - |
Lithium | Phase 3 | Bipolar Disorder Type I With Mania | - | - |
Fluorouracil | Phase 3 | Various Advanced Cancer | - | - |
Xanomeline/Trospium Chloride Capsule | Phase 3 | Alzheimer Disease | - | - |
Methotrexate (MTX) | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
Irbesartan/HCTZ | Phase 3 | Hypertension | - | - |
Iberdomide | Phase 3 | Multiple Myeloma | - | - |
Sunitinib | Phase 3 | Advanced Renal Cell Carcinoma | - | - |
Peginterferon Lambda-1a | Phase 3 | Hepatitis C Virus (HCV) | - | - |
atazanavir/ritonavir +2 NRTIs (immediate Switch Group) | Phase 3 | HIV Infections | - | - |
Atazanavir Sulphate | Phase 3 | HIV | - | - |
Atazanavir powder | Phase 3 | HIV Infections | - | - |
Deucravacitinib | Phase 3 | Psoriatic Arthritis | - | - |
Pomalidomide | Phase 3 | Multiple Myeloma | - | - |
Pegylated-Interferon-lambda | Phase 3 | Hepatitis C Virus | - | - |
BMS-986353 | Phase 3 | Systemic Sclerosis | - | - |
Glucovance (metformin HCl/glyburide) | Phase 3 | Diabetes Mellitus, Non-Insulin-Dependent | - | - |
ATV | Phase 3 | HIV Infections | - | - |
Atazanvir/ritonavir + efavirenz | Phase 3 | HIV Infections | - | - |
Atazanavir+ritonavir | Phase 3 | HIV Infections | - | - |
Belatacept | Phase 3 | Renal Transplantation | - | - |
Tacrolimus | Phase 3 | Renal Allograft Recipients | - | - |
Lenalidomide | Phase 3 | Multiple Myeloma | - | - |
Bortezomib | Phase 3 | Multiple Myeloma | - | - |
Nelfinavir mesylate | Phase 3 | HIV Infections | - | - |
Mavacamten | Phase 3 | Cardiomyopathy, Hypertrophic | - | - |
PEG-Interferon alfa 2a | Phase 3 | Hepatitis C, Genotype 1 | - | - |
Tanespimycin | Phase 3 | Advanced Malignancies | - | - |
Docetaxel | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Apixaban | Phase 3 | Lymphoma | - | - |
Brivanib | Phase 3 | Hepato Cellular Carcinoma (HCC) | - | - |
BMS-986278 | Phase 3 | Idiopathic Pulmonary Fibrosis | - | - |
Sofosbuvir | Phase 3 | Hepatitis C | - | - |
Double-blind Abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
Sorivudine | Phase 3 | HIV Infections | - | - |
Atazanavir/Ritonavir | Phase 3 | HIV | - | - |
KarX-EC | Phase 3 | Alzheimer's Disease | - | - |
BMS-986165 | Phase 3 | Psoriasis | - | - |
KarXT | Phase 3 | Alzheimer Disease | - | - |
dasatinib | Phase 3 | Myeloid Leukemia, Chronic, Accelerated Phase | - | - |
Pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Xanomeline/Trospium Chloride | Phase 3 | Mania | - | - |
warfarin | Phase 3 | Venous Thrombosis | - | - |
Efavirenz | Phase 3 | HIV Infections | - | - |
Adefovir | Phase 3 | Hepatitis B, Chronic | - | - |
Cyclosporin A | Phase 3 | Renal Transplantation | - | - |
Xanomeline Enteric Capsule | Phase 3 | Alzheimer Disease | - | - |
BMS-790052 (NS5A Replication Complex Inhibitor) | Phase 3 | Hepatitis C | - | - |
DCV 3DAA | Phase 3 | Hepatitis C Virus Infection | - | - |
Luspatercept | Phase 3 | Myelodysplastic Syndromes | - | - |
Acetylsalicylic acid | Phase 3 | Atrial Fibrillation | - | - |
Atazanavir + ritonavir + tenofovir + nucleoside | Phase 3 | HIV Infections | - | - |
BMS-986504 | Phase 3 | Metastatic Non-small Cell Lung Cancer With MTAP Deletion | - | - |
abatacept (ABA) | Phase 3 | Ulcerative Colitis | - | - |
pegIFNα-2b | Phase 3 | Hepatitis C Virus Infection | - | - |
Temozolomide | Phase 3 | Brain Cancer | - | - |
nab-Paclitaxel | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
Abatacept subcutaneous | Phase 3 | Polymyositis | - | - |
Cetuximab | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Pumitamig | Phase 3 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | - | - |
Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Phase 3 | Rheumatoid Arthritis | - | - |
Asunaprevir (ASV) | Phase 3 | Hepatitis C Virus | - | - |
Capecitabine | Phase 3 | Gastric Cancer | - | - |
Antidepressant + Aripiprazole | Phase 3 | Major Depressive Disorder | - | - |
Leucovorin | Phase 3 | Metastatic Colorectal Cancer | - | - |
Simeprevir | Phase 2 | Hepatitis C Virus | - | - |
BMS-754807 | Phase 2 | Breast Cancer | - | - |
Aurexis® | Phase 2 | Staphylococcus Aureus Bacteremia | - | - |
Vitamin K Antagonist (VKA) | Phase 2 | Thrombosis | - | - |
Letrozole | Phase 2 | Metastatic Breast Cancer | - | - |
CXL-1020 | Phase 2 | Heart Failure | - | - |
Oral Taxane | Phase 2 | Non-small Cell Lung Cancer | - | - |
BMS-986253 | Phase 2 | Cancer | - | - |
BMS-986322 | Phase 2 | Psoriasis | - | - |
BMS-986490 | Phase 2 | Advanced Solid Tumors | - | - |
MYK-491 | Phase 2 | Heart Failure With Reduced Ejection Fraction | - | - |
PSI-7977 | Phase 2 | Chronic Hepatitis C | - | - |
200 mg INX-08189 Fasted | Phase 2 | Hepatitis C | - | - |
unfractionated heparin (UFH) | Phase 2 | Antithrombotic | - | - |
MORAb-202 | Phase 2 | Neoplasms, Ovarian | - | - |
BMS-986523 | Phase 2 | Advanced Solid Malignancies | - | - |
BMS-986259 | Phase 2 | Acute Decompensated Heart Failure | - | - |
BMS-986036 | Phase 2 | Non-Alcoholic Steatohepatitis | - | - |
BMS-823778 | Phase 2 | Dyslipidemia | - | - |
Lirilumab | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Duloxetine | Phase 2 | Depression | - | - |
MDX-1100 | Phase 2 | Rheumatoid Arthritis | - | - |
BMS-986213 | Phase 2 | Advanced Solid Tumors | - | - |
Trametinib | Phase 2 | Cancer | - | - |
BMS-986158 | Phase 2 | Myelofibrosis | - | - |
BMS-986020 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
BMS-830216 | Phase 2 | Obesity | - | - |
Strata 1 CXL-1020 | Phase 2 | Heart Failure | - | - |
carboplatin + irinotecan | Phase 2 | Neoplasms | - | - |
BMS-986340 | Phase 2 | Cervical Cancer | - | - |
Anastrozole | Phase 2 | Breast Cancer | - | - |
BMS-986446 | Phase 2 | Alzheimer Disease, Early Onset | - | - |
SAR302503 (TG101348) | Phase 2 | Myelofibrosis | - | - |
HNO Donor | Phase 2 | Heart Failure | - | - |
BMS-986435 | Phase 2 | Heart Failure | - | - |
ixabepilone | Phase 2 | Esophageal Cancer | - | - |
Cyclophosphamide | Phase 2 | Breast Cancer | - | - |
BMS-790052 | Phase 2 | Hepatitis C Infection | - | - |
BMS-986142 | Phase 2 | Rheumatoid Arthritis | - | - |
CC-92480 | Phase 2 | Multiple Myeloma | - | - |
Cabiralizumab | Phase 2 | Advanced Pancreatic Cancer | - | - |
CXL-1427 | Phase 2 | Heart Failure | - | - |
Peginterferon α-2a | Phase 2 | Hepatitis C | - | - |
BMS-986156 | Phase 2 | Solid Tumors | - | - |
MDX-010 / MDX-010 + Docetaxel | Phase 2 | Prostate Cancer | - | - |
Lamivudine | Phase 2 | Hepatitis B Virus | - | - |
BMS-986458 | Phase 2 | Relapsed/Refractory Non-Hodgkin Lymphoma | - | - |
Thymoglobulin | Phase 2 | Kidney Transplantation | - | - |
BMS-690514 | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |
Cyclosporine A | Phase 2 | Renal Transplant | - | - |
Ritonavir | Phase 2 | HIV Infections | - | - |
Dexamethasone | Phase 2 | Multiple Myeloma | - | - |
Abatacept (BMS-188667) | Phase 2 | Rheumatoid Arthritis | - | - |
BMS-986288 | Phase 2 | Advanced Cancer | - | - |
BMS-650032 | Phase 2 | Hepatitis C Virus | - | - |
CC-486 | Phase 2 | Leukemia, Myeloid, Acute | - | - |
BMS-986141 | Phase 2 | Thrombosis | - | - |
Aurexis® (tefibazumab) | Phase 2 | Staphylococcus Aureus | - | - |
Cabazitaxel | Phase 2 | Prostate Cancer | - | - |
Pegylated Interferon Lambda | Phase 2 | Hepatitis C | - | - |
Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC) | Phase 2 | HIV Infections | - | - |
BMS-986369 | Phase 2 | Relapsed or Refractory T-cell Lymphomas | - | - |
5-fluorouracil (5-FU) | Phase 2 | Colorectal Cancer | - | - |
Peginterferon alpha-2a | Phase 2 | Hepatitis C Infection | - | - |
Exemestane + Dasatinib | Phase 2 | Breast Cancer | - | - |
Dasatinib 100 mg | Phase 2 | Breast Cancer | - | - |
MDX-010 | Phase 2 | Breast Cancer | - | - |
BMS-986004 75 mg IV | Phase 2 | Immune Thrombocytopenic Purpura | - | - |
Vemurafenib | Phase 2 | Melanoma | - | - |
KOS-1584 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
INX-08189 50 mg | Phase 2 | Healthy | - | - |
Pegylated-interferon alfa-2a | Phase 2 | Chronic Hepatitis C | - | - |
BMS-708163 | Phase 2 | Alzheimer's Disease | - | - |
BMS-954561 | Phase 2 | Diabetic Peripheral Neuropathic Pain | - | - |
CCR2 Antagonist | Phase 2 | Type 2 Diabetes | - | - |
BMS-986012 (anti-fucosyl-GM1) | Phase 2 | Small Cell Lung Cancer | - | - |
BMS-986482 | Phase 2 | Advanced Solid Tumors | - | - |
BMS-791325 | Phase 2 | Hepatitis C Virus | - | - |
Daratumumab | Phase 2 | Advanced Cancer | - | - |
BMS-562086 | Phase 2 | Irritable Bowel Syndrome | - | - |
Elotuzumab (BMS-901608) | Phase 2 | Multiple Myeloma | - | - |
BMS-986012 | Phase 2 | Extensive-stage Small Cell Lung Cancer | - | - |
BMS-833923 | Phase 2 | Leukemia | - | - |
BMS-986165 Dose A | Phase 2 | Active Psoriatic Arthritis | - | - |
BMS-986315 | Phase 2 | Advanced Solid Tumor | - | - |
BMS-986470 | Phase 2 | Anemia, Sickle Cell | - | - |
BMS-790052 (NS5A Inhibitor) | Phase 2 | Hepatitis C | - | - |
BMS-986525 | Phase 2 | Relapsed/Refractory Small Cell Lung Cancer | - | - |
BMS-813160 | Phase 2 | Advanced Cancer | - | - |
Sirolimus | Phase 2 | Disorder Related to Renal Transplantation | - | - |
BMS-914392 | Phase 2 | Atrial Fibrillation | - | - |
Erlotinib | Phase 2 | Non Small Cell Lung Cancer | - | - |
branebrutinib | Phase 2 | Autoimmune Disorder | - | - |
Fulvestrant | Phase 2 | Advanced Breast Cancer | - | - |
Megestrol acetate | Phase 2 | Anorexia | - | - |
BMS-582949 | Phase 2 | Vascular Diseases | - | - |
Cobimetinib | Phase 2 | Microsatellite Unstable Colorectal Cancer | - | - |
Afimetoran | Phase 2 | Systemic Lupus Erythematosus | - | - |
BMS-820836 | Phase 2 | Depression | - | - |
pegIFN | Phase 2 | Hepatitis B Virus | - | - |
Thalidomide | Phase 2 | Relapsed and/or Refractory Multiple Myeloma | - | - |
BMS-986449 | Phase 2 | Advanced Solid Tumors | - | - |
Pegylated interferon alfa-2a | Phase 2 | Hepatitis C Virus | - | - |
Cyclosporine | Phase 2 | Graft Rejection | - | - |
Irinotecan | Phase 2 | Colorectal Cancer (CRC) | - | - |
Anti-CD137 (4-1BB) (BMS-663513) | Phase 2 | Melanoma | - | - |
BMS-777607 | Phase 2 | Advanced Solid Tumors | - | - |
Fedratinib | Phase 2 | Primary Myelofibrosis | - | - |
BMS-986231 | Phase 2 | Cardiac Failure | - | - |
BMS-908662 | Phase 2 | Colorectal Cancer | - | - |
BMS-770767 | Phase 2 | Diabetes Type 2 | - | - |
BMS-986507 | Phase 2 | Lung Cancer | - | - |
BMS-986263 | Phase 2 | Hepatic Cirrhosis | - | - |
INX-08189 50 mg QD X 5 days | Phase 2 | Healthy | - | - |
bendamustine | Phase 2 | Hodgkin Disease | - | - |
BMS-936557 (Anti-IP-10 Antibody) | Phase 2 | Crohn's Disease | - | - |
brivanib (active) | Phase 2 | Hepatocellular Carcinoma (HCC) | - | - |
MDX-010 (CTLA-4) | Phase 2 | Melanoma | - | - |
BMS-986249 | Phase 2 | Advanced Cancer | - | - |
BMS-986207 | Phase 2 | Broad Solid Tumor | - | - |
BMS-986517 | Phase 2 | Solid Tumours | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)